Shimmer, a provider of wearable sensor technology, announces a long-term supply contract with U.S. client Emerge Diagnostics. Worth $10 million over the next three years, Shimmer will provide the core platform on which Emerge Diagnostics has developed a class II medical device designed to perform an Electrodiagnostic Functional Assessment (EFA). This compact, portable and wireless device provides a new, cost-effective standard in the diagnosis and treatment of soft tissue injuries, particularly in relation to occupational injuries.
The EFA can distinguish an acute injury from a chronic one and can assist with better treatment of soft tissue injuries to identify when they originally occurred. Emerge Diagnostics has received FDA 510K approval with the support of the Shimmer team.
According to U.S. Bureau of Labor Statistics, soft tissue injuries account for an estimated $200 billion annually in lost work hours with workers compensation making up the largest component of this cost. This new solution provides a cost effective, portable, wireless and accurate system to diagnose the severity of conditions to improve claim management and clinical outcomes.
EFA testing consists of a comprehensive body monitoring system including 28 wearable sensors harvesting a range of movement and bio-physical data, Shimmer’s flexible and customizable platform allows for the rapid development of a solution that can be tailored at every step of the process without lengthy and costly hardware and application development.
Shimmer is headquartered in Dublin, Ireland, and has an R&D center in Boston, Mass. Emerge Diagnostics is a California-based company created to commercialize the Electrodiagnostic Functional Assessment (EFA).